Availability of Liposomes as Drug Carriers to the Brain

Acta Medica Okayama

Volumn 50, Issue 2, 1996, Pages 67-72

  Kobayashi, Kazuko ^a   Han, Mei ^a   Watarai, Shinobu ^a   Yasuda, Tatsuji ^a  

^a OKAYAMA UNIVERSITY MEDICAL SCHOOL   (Japan)

Author keywords

Brain targeting; Liposomes; Mouse; THA (9 amino 1,2,3,4 tetrahydroacridine)

Indexed keywords

DRUG CARRIER; LIPOSOME; TACRINE;

ANIMAL; ARTICLE; BLOOD BRAIN BARRIER; BRAIN; CHEMISTRY; MALE; METABOLISM; MOUSE; MOUSE STRAIN; TISSUE DISTRIBUTION;

ANIMALS; BLOOD-BRAIN BARRIER; BRAIN; DRUG CARRIERS; LIPOSOMES; MALE; MICE; MICE, INBRED STRAINS; TACRINE; TISSUE DISTRIBUTION;

EID: 0030123952     PISSN: 0386300X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. McCulloch J: Ischaemic brain damage: Prevention with competitive and non-competitive antagonists of N-methyl-D-aspartate receptors. Arzneim-Forsch (1991) 41, 319-324.
2. Barb CR, Kineman RD, Kesner JS, Rampacek GB and Kraeling RR: Luteinizing hormone secretion following intracerebroventricular administration of morphine in the prepuberal gilt. Life Sci (1989) 45, 691-696.
3. Yoshikawa T and Pardridge WM: Biotin delivery to brain with a covalent conjugate of avidin and a monoclonal antibody to the transferrin receptor. J Pharmacol Exp Ther (1992) 263, 897-903.
4. Mayhew E and Papahadjopoulos D: Therapeutic applications of liposomes; in Liposomes, Ostro MJ ed, Marcel Dekker Inc, New York, (1983) pp289-341.
5. Herman EH, Rahman A, Ferrans VJ, Vick JA and Schein PS: Prevention of chronic doxorubicin cardiotoxicity in beagles by liposomal encapsulation. Cancer Res (1983) 43, 5427-5432.
6. van Hoesel QGCM, Steerenberg PA, Crommelin DJA, van Dijk A, van Oort W, Klein S, Douze JMC, de Wildt DJ and Hillen FC: Reduced Cardiotoxicity and Nephrotoxicity with preservation of antitumor activity of doxorubicin entrapped in stable liposomes in the LOU/M Wsl rat. Cancer Res (1984) 44, 3698-3705.
7. Surolia A and Bachhawat BK: Monosialoganglioside liposome-entrapped enzyme uptake by hepatic cells. Biochim Biophys Acta (1977) 497, 760-765.
8. Onuma M, Yasutomi Y, Yamamoto M, Watarai S, Yasuda T and Kawakami Y: Antitumor effect of adriamycin entrapped in liposomes conjugated with anti-bovine tumor antigen monoclonal antibody in leukemic cows. J Vet Med Ser B (1989) 36, 139-147.
9. Basu MK: Liposomes in drug targeting. Biotechnol Genet Eng Rev (1994) 12, 383-408.
10. Yagi K, Naoi M, Sakai H, Abe H, Konishi H and Arichi S: Incorporation of enzyme into the brain by means of liposomes of novel composition. J Appl Biochem (1982) 4, 121-125.
11. Umezawa F and Eto Y: Liposome targeting to mouse brain: Mannose as a recognition marker. Biochem Biophys Res Commun (1988) 153, 1038-1044.
12. Summers WK, Majovski LV, Marsh GM, Tachiki K and Kling A: Oral tetrahydroaminoacridine in long-term treatment of senile dementia, Alzheimer type. N Engl J Med (1986) 315, 1241-1245.
13. Deamer DW and Uster PS: Liposome preparation: Methods and mechanisms; in Liposomes, Ostro MJ ed, Marcel Dekker Inc, New York (1983) pp27-51.
14. Mayor LD, Tai LCL, Bally MB, Mitilenes GN, Ginsberg RS and Cullis PR: Characterization of liposomal systems containing doxorubicin entrapped in response to pH gradients. Biochim Biophys Acta (1990) 1025, 143-151.
15. 18 extraction. J Chromatogr (1983) 274, 388-392.
16. Hsu RS, DiLeo EM, and Chesson SM: High-performance liquid chromatography for the determination of tacrine and its metabolites in plasma. J Chromatogr (1990) 530, 170-176.
17. Gregoriadis G, Senior J and Wolff B: Targeting of liposomes: Optimization of vesicle behaviour in vivo; in Medical Application of Liposomes, Yagi K ed, Japan Scientific Societies Press, Tokyo (1986) pp67-79.
18. Nielsen JA, Mena EE, Williams IH, Nocerini MR and Liston D: Correlation of brain levels of 9-amino-1,2,3,4-tetrahydroacridine (THA) with neurochemical and behavioral changes. Eur J Pharmacol (1989) 173, 53-64.
19. 1-containing liposomes. Biochim Biophys Acta (1992) 1104, 95-101.
20. Schackert G, Fan D, Nayar R and Fidler IJ: Arrest and retention of multilamellar liposomes in the brain of normal mice or mice bearing experimental brain metastases. Sci Cancer Ther (1989) 5, 73-79.
21. Jonah MM, Cerny EA and Rahman YE: Tissue distribution of EDTA encapsulated within liposomes containing glycolipids or brain phospholipids. Biochim Biophys Acta (1978) 541, 321-333.
22. Allen TM, Hansen C and Rutledge J: Liposomes with prolonged circulation times: Factors affecting uptake by reticuloendothelial and other tissues. Biochim Biophys Acta (1989) 981, 27-35.
23. Blume G and Cevc G: Liposomes for the sustained drug release in vivo. Biochim Biophys Acta (1990) 1029, 91-97.
24. Gabizon A and Papahadjopoulos D: Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors. Proc Natl Acad Sci USA (1988) 85, 6949-6953.
25. Oku N, Namba Y and Okada S: Tumor accumulation of novel RES-avoiding liposomes. Biochim Biophys Acta (1992) 1126, 255-260.
26. Fielding RM: Liposomal drug delivery: Advantages and limitations from a clinical pharmacokinetic and therapeutic perspective. Clin Pharmacokinet (1991) 21, 155-164.